T he vascular endothelial growth factor (VEGF) family of ligands and its tyrosine kinase receptors are critical regulators of angiogenesis and lymphangiogenesis. Of the VEGF receptors, VEGF receptor (VEGFR)-3 has been shown to be critical for developmental angiogenesis and lymphangiogenesis, as VEGFR-3 null mice die due to a failure in remodeling of the primary vascular plexus. 1 VEGFR-3 expression is maintained in blood endothelial cell lymphatic precursors but in adulthood becomes restricted to lymphatic endothelial cells with the exception of few blood capillaries in some organs. 2 As a receptor for VEGF-C, VEGFR-3 is essential for proper development of the lymphatic vasculature. [3] [4] [5] The lymphatic vasculature is an integral part of normal physiology. Lymphatic vessels act as a conduit for immune cells for assistance in immune surveillance, return extravasated interstitial fluid to the blood, and absorb dietary lipids in the intestine. 2,6 -8 In the adult mouse, VEGFR-3 is critical for signaling in response to VEGF-C/D-induced lymphatic vessel growth, 9 which occurs mostly as a result of inflammation. 2 Recent work has demonstrated that the transcription factors Prox1, NF-B, and Tbx1 are critical for VEGFR-3 gene expression. 10, 11 However, little is known about the mechanisms by which VEGFR-3 expression is controlled during inflammatory lymphangiogenesis 12 and is the subject of this study.
Recently, posttranscriptional regulators of gene expression have gained attention. MicroRNAs (miRNAs) are endogenous, nonprotein coding small RNAs that play important roles in the posttranscriptional regulation of target genes by directing target mRNAs for translational repression or destabilization. The collection of miRNA-class regulatory RNAs in invertebrates and mammals was expanded by the finding of short hairpin introns known as mirtrons. 13, 14 Mirtrons bypass Drosha cleavage by using the spliceosome to generate their precursor ends (pri-miRNAs). Although generated differently from conventional miRNAs, mirtrons are also cleaved by Dicer to generate functional miRNAs that can also regulate genes posttranscriptionally. Recent work has indicated a role for miRNAs in angiogenesis 15 and determination of lymphatic endothelial cell lineage fate from blood endothelial cells by regulation of Prox-1. 16, 17 However, it is not known if miRNAs can directly regulate VEGFR-3-a critical receptor involved in lymphangiogenesis and angiogenesis.
In this study, we show that miR-1236 is expressed in endothelial cells and binds to the 3Ј untranslated region (UTR) of the VEGFR-3 gene, resulting in translational inhibition of VEGFR-3. This work reveals that miR-1236 may represent a posttranscriptional mechanism by which VEGFR-3 expression is fine-tuned in lymphatic endothelial cells. Our work is the first example of a miRNA that targets VEGFR-3 and may have important implications for the control of VEGFR-3 during inflammatory lymphangiogenesis.
Methods

DNA Constructs/Reporter Gene Assays
From human lymphatic endothelial cells (HLEC), cDNAs encoding the entire 3ЈUTR of VEGFR-3 (1.69kb) was amplified by reverse transcription-PCR from HLEC RNA and was directionally subcloned into the NotI-XhoI sites downstream of the Renilla luciferase in the psiCHECK2 vector that also contains a constitutively expressed firefly luciferase gene. Construct was confirmed by sequencing at WM Keck Facility at Yale University. Next, the region complementary to the miR-1236 predicted seed sequence in position 144 to 150 of the human VEGFR-3 3ЈUTR, GGAAGA, was scrambled to TCTAGA (mut Vegfr3 3ЈUTR), using the QuikChange™ Site-Directed Mutagenesis Kit. This construct was also confirmed by sequencing. Luciferase output was quantified with a Berthold Lumat LB 9501 luminometer and renilla luciferase activity was normalized to the corresponding firefly luciferase activity using a Dual-Glo Luciferase Assay System (Promega) and reported as the percentage of control cells cotransfected with the same concentration of control mimic or miR-1236 mimic. Experiments were performed 4 times using triplicates.
VEGFR-3 Lentiviral Expression Construct
Full-length human VEGFR-3 was amplified using PCR from a VEGFR-3 mammalian expression plasmid, and BamHI and Not1 restriction sites were introduced at either end of the cDNA. The PCR product was subcloned into the target lentiviral vector pLex (Open-Biosystems), resulting in pLex-VEGFR-3. The VEGFR-3 cDNA insert was confirmed by DNA sequencing and VEGFR-3 protein expression from pLex-VEGFR-3 was confirmed by Western blotting after transient transfection into 293T cells.
MiRNA Analysis
MiRNAs were isolated from cells using miRNeasy kit (Qiagen) according to the manufacturer's instructions. Quantitative reverse transcription-PCR (qRT-PCR) assays were performed using a TaqMan miRNA assay kit (Applied Biosystems) for the mature miRNA using the target-specific stem-loop reverse transcription primer. The forward primer sequences for hsa-miR-1236 and RNU6B were purchased from Applied Biosystems and used for PCR validation. qRT-PCR was performed by using iQ SYBR Green Supermix on C1000 Thermal Cycler (Bio-Rad).
Statistical Analyses
All data are expressed as meanϮSEM. Statistical analysis was performed with a 2-tailed Student's paired t test. Statistical significance for probability values are as follows: *Ͻ0.05; **Ͻ0.01; ***Ͻ0.001. For analysis, positive staining and area was quantified with Image Pro Plus Software (MediaCybernetics).
The detailed methods that we have published are provided in the online-only Data Supplement. These methods include lymphatic endothelial cell (EC) culture, transfection, immunoblotting for VEGFR2/3 signaling, immunofluorescence, cell migration/tube formation assays, and in vivo lymphangiogenic assays as we described previously. 18 
Results
Inflammatory Lymphangiogenesis In Vivo Is Transient
We have observed that lymphangiogenesis is transient in all models we have examined, including VEGF-induced cornea lymphangiogenesis, 18 VEGF-induced lymph node (LN) lymphangiogenesis, 18 and inflammation-mediated LN lymphangiogenesis by immunization with oxazolone ( Figure 1A ). In the oxazolone skin painting model, oxazolone-induced inflammation elicits a profound LN lymphangiogenic response. 19 In this system, LN lymphangiogenesis peaked on days 3 to 4 followed by regression by day 7 ( Figure 1A with quantifications in Figure 1B ). We determined the levels of lymphangiogenic growth factors (VEGF-A and VEGF-C) by qRT-PCR and found that their expressions in LNs were even higher at day 7 compared to day 3 postoxazolone challenge ( Figure IA in the online-only Data Supplement). Rececently, it has been shown that inflammation can decrease VEGFR-3 protein and transcript during oxazolone challenge, concomitant with the expression of inflammatory cytokines. 20, 21 Therefore, we hypothesized that inflammatory cytokines may inhibit oxazolone-induced lymphangiogenesis. Consistent with a recent report, 20 we found that proinflammatory cytokines such as tumor necrosis factor-␣ (TNF), interleukin-1␤ (IL-1␤) and interferon ␥ (IFN-␥) were increased after oxazolone challenge ( Figure IB in the online-only Data Supplement) with IL-1␤ at a much higher level. Although TNF and IFN-␥ have been shown to drive and inhibit lymphangiogenesis, respectively, 22,23 the effect of IL-1␤ on lymphangiogenesis is not well-characterized. We determined a direct effect of IL-1␤ on lymphangiogenesis in a VEGF-C-induced HLEC tube formation assay. In the presence of IL-1␤, VEGF-Cinduced tube formation in a Matrigel was significantly suppressed ( Figure 1C with quantification in Figure 1D ). To determine the mechanism for decreased tube formation by IL-1␤, we analyzed protein expression of the VEGF-C receptors, VEGFR-2 and VEGFR-3. As we reported recently, 18 protein analysis of VEGFR-3 by Western blot revealed 3 bands ( Figure 1E ). Although the band at 175 kDa is considered to be the intracellular and unglycosylated precursor, the band with molecular weight 125 kDa represents the mature form of VEGFR-3. 24, 25 Stimulation of HLEC with IL-1␤ for 24 hours strongly reduced expression of VEGFR-3 but not VEGFR-2 ( Figure 1E ). A similar effect was found by stimulation with other inflammatory cytokines, namely IL-1␣ and TNF ( Figure IC in the online-only Data Supplement). However, IL-1␤ did not significantly affect VEGFR-3 mRNA as measured by qRT-PCR ( Figure 1F ). These results suggested that IL-1␤ may regulate VEGFR-3 at a posttranscriptional level.
Induction of MiR-1236 by IL-1␤
The results above prompted us to examine if VEGFR-3 expression can be regulated by miRNA. To this end, Target-Scan (www.targetscan.org) and other miRNA prediction algorithms were used to search for miRNA binding sites in the VEGFR-3 3ЈUTR. In silico analysis revealed a highly conserved site in the VEGFR-3 3ЈUTR as a putative target of a 7mer-m8 site in the seed region of miR-1236 ( Figure 2A ). We chose miR-1236 as a candidate because of its relatively high context percentile score (73%, as TargetScan defines a favorable score as being 50 -100) and the possibility of being functionally testable in vivo, as the predicted binding site is also conserved in mice. In contrast, miR-132, miR 323 to 5p, miR 200b, and miR200c, which have a higher percentile score than miR-1236, but do not have predicted 3ЈUTR target sites that are conserved in mice, making it difficult to test the effectiveness in vivo. Using qRT-PCR with TaqMan primers that recognize the mature miRNA species, we detected a pan-endothelial expression of miR-1236. HLEC had higher expression of miR-1236 than human vein endothelial cells and human aortic EC but lower than human SMCs ( Figure 2B ). Expression of miR-1236 was specific to human cells, using mouse ECs as a control ( Figure 2B ). Because lymphatic cells express endogenous VEGFR-3, we used HLEC to determine the effect of miR-1236 on VEGFR-3 expression. Next, we determined if miR-1236 is regulated by inflammatory cytokines in HLEC. Stimulation of HLEC with inflammatory cytokines that downregulate VEGFR-3 caused an upregulation of miR-1236 ( Figure IIA in the online-only Data Supplement). Stimulation of HLEC with IL-1␤ led to the most significant (Ͼ3-fold) upregulation of miR-1236, peaking at 24 hours poststimulation ( Figure 2C ). Expression of the host gene of miR-1236, negative elongation factor-E, was also confirmed in HLEC. Furthermore, we observed a trend in the upregulation of host gene, negative elongation factor-E upon stimulation with IL-1␤ ( Figure IIB in the online-only Data Supplement). The kinetics of miR-1236 induction is consistent with IL-1␤induced downregulation of VEGFR-3 at 24 hours ( Figure 1E ). These data suggest that IL-1␤-induced miR-1236 may negatively regulate VEGFR-3 expression in HLEC. Human lymphatic endothelial cells (HLEC) were stimulated with interleukin-1␤ (IL-1␤) (5 ng) for 24 hours. Cells were then seeded to Matrigel and cultured with 3% serumϩVEGF-C (100 ng/mL) for 6 hours and representative images are shown in C. Branch points as indicated by arrowheads were quantified in D. Data are meanϮSEM from 3 independent experiments, **PϽ0.01. Scale bar, 100 m. E, F, Effects of IL-1␤ on vascular endothelial growth factor receptor (VEGFR)-3 protein and mRNA. HLEC were stimulated with IL-1␤ (5 ng) for 24 hours. VEGFR-3 and VEGFR-2, and ICAM-1 proteins were detected by Western blot with respective antibodies. Beta-actin was used as a loading control and relative levels of VEGFR-3 are indicated below the blot with untreated group as 1.0 (E). VEGFR-3 mRNA was assessed by qRT-PCR with normalization to gapdh mRNA (F). Data are meanϮSEM from 3 independent experiments.
Endogenous miR-1236 in Primary Human Lymphatic Endothelial Cells Regulates VEGFR-3 Expression by Binding to the VEGFR-3 3UTR
We were able to efficiently transfect siRNA into HLEC ( Figure III in the online-only Data Supplement). To verify if miR-1236 targets VEGFR-3, HLEC were transfected with a control anti-miR or anti-miR-1236. Inhibition of endogenous miR-1236 was confirmed by qRT-PCR ( Figure 3A ). Total VEGFR-3 was modestly increased in HLEC ( Figure 3B ), suggesting that endogenous miR-1236 in primary human lymphatic endothelial cells may partially contribute to regulation of VEGFR-3 protein expression. To further determine how miR-1236 regulates VEGFR-3 expression in HLEC, we took an overexpression approach. Introduction of miR-1236 to HLEC in culture resulted in significant downregulation of total VEGFR-3 protein, but not mRNA, indicating that miR-1236 targets the VEGFR-3 gene for translational inhibition ( Figure 3C and 3D). Importantly, neither VEGFR-2 transcript nor protein was significantly decreased after overexpression of miR-1236 ( Figure 3C and 3D).
In order to confirm VEGFR-3 as a bona fide direct target of miR-1236, we sought to determine whether miR-1236 was able to bind to and repress VEGFR-3 mRNA. Therefore, the entire 1.69 kb VEGFR-3 3ЈUTR, containing the predicted consensus miR-1236 binding site was cloned into the psi-CHECK2 luciferase reporter construct. Next, we mutated the putative binding site of the original construct by substituting three base pairs ( Figure 3E ). We then tested these predicted miRNA/mRNA interactions based on luciferase activity as subsequently measured in COS cells. In contrast to cotransfection of the VEGFR-3 reporter construct together with a control miRNA, cotransfection of the VEGFR-3 reporter construct together with miR-1236 significantly reduced luciferase activity ( Figure 3F ). This decrease in luciferase activity was seen in a concentration-dependent manner (not shown). Furthermore, cotransfection of miR-1236 with a mutant VEGFR-3 3ЈUTR reporter construct into which only a 3-bp mutation in the miR-1236 binding site was introduced did not repress luciferase activity as seen by miR-1236 on the wild-type construct ( Figure 3F , mut VEGFR-3 3ЈUTR). In addition, no significant repression was found by cotransfection of the psiCHECK2 vector backbone together with miR-1236 ( Figure 3F ). Taken together, these data suggest that miR-1236 directly binds to VEGFR-3 to negatively regulate VEGFR-3 expression.
MiR-1236 Negatively Regulates VEGFR-3-Dependent Signaling in Primary Human Lymphatic Endothelial Cells
We then determined if miR-1236 regulates VEGFR-3 signaling in HLEC. PI3K-Akt, and MAPK (ERK1/2) signaling pathways are reported to be the major downstream effectors in VEGFR-3 signaling. We have recently shown in HLEC that VEGF-A activates VEGFR-2, whereas VEGF-C activates VEGFR-3 strongly and VEGFR-2 weakly. However, a mutant form of VEGF-C (C156S, CS) specifically binds to and activates VEGFR-3 but not VEGFR-2 18 (also see Figure  4 ). We have also reported that VEGF-C and VEGF-CS strongly activate the VEGFR-3-Akt axis but not the PLC-␥ axis. In contrast, VEGF-A strongly activates VEGFR-2-PLC-␥/ERK1/2 pathways. 18 Therefore, we examined effects of miR-1236 on VEGF-C, VEGF-CS, and VEGF-A-induced signaling in HLEC. Overexpression of miR-1236 in HLEC significantly reduced the total level of VEGFR-3 as well as VEGF-C or VEGF-CS-induced phosphorylation of VEGFR-3 ( Figure 4A and 4B) . The reduced phosphorylation of VEGFR-3 was due to reduced total levels of VEGFR-3, as overexpression of VEGFR-3 lacking the 3ЈUTR rescued VEGFR-3 signaling ( Figure IV in the online-only Data Supplement). MiR-1236 also weakly reduced VEGF-C-induced phosphorylation of VEGFR-2 without effects on the total levels of VEGFR-2 ( Figure 4A ), perhaps partially due to heterodimerization between VEGFR2 and VEGFR3. 26 1236 -mediated reduction of p-VEGFR-2 was also rescued by overexpression of VEGFR-3 ( Figure IV in the online-only Data Supplement). Moreover, VEGF-C and VEGF-CS-induced phosphorylation of downstream effectors Akt and ERK1/2 were also decreased by miR-1236 ( Figure 4A and  4B) . In contrast, miR-1236 had no significant effect on VEGF-A-induced VEGFR-2-PLC-␥/ERK1/2 signaling (Figure 4C) . With the exception of VEGFR-3, total levels of VEGFR-2, Akt, PLC-␥, and ERK1/2 were not altered by miR-1236 ( Figure 4A-4C) . These data suggest that miR-1236 specifically regulates VEGFR-3-dependent signaling in lymphatic endothelial cells.
MiR-1236 Regulates VEGFR-3-Dependent Functions in Primary Human Lymphatic Endothelial Cells
VEGFR-3 has been shown to be important for growth, survival, and migratory signals in HLEC. 27 Therefore, we determined if miR-1236 repression of VEGFR-3 signaling would have negative functional outcomes in HLEC on 2 well-known functions for lymphatic endothelial cellsmigration and tube formation. A control miR or miR-1236 was transfected into HLEC, and cell migration was assessed by a scratch wound assay. Overexpression of miR-1236 significantly reduced scratch closure by HLECs in response to VEGF-C compared to the control miR ( Figure 5A with quantification in 5B). Proliferation might minimally contribute to the effect in this assay as cell cycle analysis showed miR-1236 weakly inhibited VEGF-C (but not VEGF-A)induced cell proliferation ( Figure V in the online-only Data Supplement). Next, we determined the effect of miR-1236 on tube formation by HLEC in a Matrigel assay, in which endothelial cells align to form elongated tube-like structures. Compared to the control miR, overexpression of miR-1236 in HLEC led to a significant reduction in the ability of HLEC to form tube-like structures in a Matrigel in response to VEGF-C ( Figure 5C with quantification in 5D). Taken together, these results suggest that miR-1236 can attenuate VEGF-C/VEGFR-3 mediated functions in HLEC.
MiR-1236 Reduces Lymphangiogenesis and Angiogenesis In Vivo
Development of the murine retina is well described. 28 Interestingly, VEGFR-3 is expressed on the developing retina. 29 Because there is no murine homologue to miR-1236, we injected miR-1236 into mouse tissues to determine an in vivo effect. Intravitreous injection of FITC-labeled siRNA was taken up by the retina (Figure VI in the online-only Data Supplement). After a single intravitreous injection of miR-1236, we found that miR-1236 was detectable up to 5 days ( Figure 6A ), indicating that miR-1236 was stable in the vitreous chamber and retina. Importantly, VEGFR-3, but not VEGFR-2 or neuropilin-2 (NRP-2, a VEGF-A coreceptor), was decreased from mouse retinas that were injected with miR-1236, relative to control mimics ( Figure 6B ). Isolectin B4 staining revealed a tortuous and disorganized pattern of blood vessels in the right eye (miR-1236) compared to the left eye (control miR) ( Figure 6C ). Furthermore, miR-1236treated retina showed dysregulated vascularization with a reduced number of sprouts on the leading edge (tip cells) and ( Figure 6C with quantification in 6D), consistent with the phenotypes on VEGFR-3 inhibition as described by Tammela et al. 29 To assess the effects of miR-1236 on ear skin lymphangiogenesis, we treated 12 days-old mice undergoing postnatal ear lymphangiogenesis with 2 injections of miR-1236 and monitored vascular growth 8 days later. At the site of injection, LYVE-1 positive lymphatic vessels in the ear were decreased approximately 30% relative to the control miR ( Figure 6E with quantification in 6F). These results suggest that overexpression of miR-1236 can decrease lymphangiogenesis in vivo, through inhibition of VEGFR-3 signaling.
Discussion
In the study presented here, we define a novel mechanism of VEGFR-3 posttranscriptional regulation mediated by cytokine and microRNA. It was recently found that in the setting of acute skin inflammation in mice, VEGFR-3 mRNA and protein is strongly downregulated in inflamed lymphatics. This decrease correlates with the appearance of inflammatory cytokines, including IL-1␤. 20 IL-1␤, a multifunctional mediator of the inflammatory response, is among the cytokines 4 . miR-1236 regulates vascular endothelial growth factor receptor (VEGFR)-3 dependent signaling in primary human lymphatic endothelial cells. A, C, Human lymphatic endothelial cells (HLEC) were transfected with control (ctrl) miR or miR-1236. After 48 hours, cells were subsequently serum-starved overnight followed by treatment with vascular endothelial growth factor (VEGF)-C (100 ng/mL) (A), VEGF-C Cys156Ser (VEGF-CS, 250 ng/mL) (B), or VEGF-A (50 ng/mL) (C) for indicated times. Phospho-and total VEGFR-3, VEGFR-2, Akt, ERK, and PLC␥ were detected by Western blot with respective antibodies. Relative levels of phospho-and total proteins were quantified by taking untreated ctrl miR as 1.0. Similar results were obtained from additional two experiments.
produced during oxazolone-induced inflammation. 20 Despite IL-1␤ having a lymphangiogenic response in vivo, it was reported to be indirect, through production of VEGFs. 30 -32 To determine the direct effects of IL-1␤ on HLEC, we introduced IL-1␤ to HLEC in culture. Interestingly, IL-1␤ downregulated VEGFR-3 protein but not the transcript in cultured lymphatic ECs, leading to decreased HLEC function. To investigate a potential role for miRNA in VEGFR-3 regulation in HLEC, in silico analysis using TargetScan predicted a conserved binding site in the 3Ј UTR of VEGFR-3, complementary to hsa-miR-1236. Hsa-miR-1236 is an experimentally cloned mirtron, first mentioned by Berezikov et al using a computational screen for conserved mammalian mirtrons. 33 We cloned the 3Ј UTR of VEGFR-3 and subsequent luciferase assays identified a miR-1236 binding site between nucleotides 144 and 150 of the human VEGFR-3 3Ј UTR. This region of the 3ЈUTR is conserved across species including analyses of the human, chimpanzee, rhesus macaque, mouse, and rat VEGFR-3 UTRs. From our in vitro studies, we conclude that the VEGFR-3 transcript is a target of miR-1236. miR-1236 was able to decrease VEGFR-3 protein, but not VEGFR-3 transcript. Compared to the control miR, miR-1236 caused reduction of VEGFR-3 protein and led to a significant reduction in the signaling response to the lymphangiogenic growth factor, VEGF-C. No significant difference was found after stimulation with a VEGFR-2 specific ligand, VEGF-A, suggesting a VEGFR-3 specific effect. Importantly, miR-1236 -mediated inhibition on VEGFR-3 signaling resulted in reduced lymphatic EC migration and tube formation, as well as lymphangiogenesis in vivo.
Another important finding is that miR-1236 is inducible by IL-1␤ signaling in lymphatic endothelial cells. These results support a model that miR-1236 functions as a negative regulator of VEGF-C/VEGFR-3 signaling and inflammationinduced lymphangiogenesis ( Figure 6G ). Inflammatory cytokines such as IL-1␤ contribute to initial lymphangiogenesis, in part, by inducing expression of VEGFs and adhesion molecules such as ICAM-1, which recruits inflammatory cells. IL-1␤ also induces miR-1236, which in turn suppresses VEGFR-3-dependent signaling. Negative feedback mechanisms have been previously demonstrated for VEGF/VEGFR signaling. Specifically, VEGF-A via VEGFR-2 induces acti- vation/expression of Notch, which in turn suppresses VEGFR-2 expression/activity, therefore negatively regulating angiogenesis. 34 -36 In addition, VEGFR-2/3 is also negatively regulated by many other mechanisms, including phosphatases, endocytosis, and ubiquitination. 37-39 VEGFR-2 has been recently shown to be regulated by microRNA-424 and microRNA. 16, 40 Our study has demonstrated, for the first time, that VEGFR-3 signaling is feedback regulated by microRNA. Our data suggests that miR-1236 activity could play a role in the regulation of VEGFR-3 expression in lymphatic and blood vasculature during human hemangiogenesis. Modulation of VEGFR-3 levels using miR-1236 may represent a promising approach for the treatment of human disease in which a decrease in VEGFR-3 would be beneficial. We cannot rule out other targets of miR-1236, as exogenous VEGFR-3 failed to completely rescue tube formation and migration despite rescuing VEGFR-3 signaling ( Figure  IV in the online-only Data Supplement). However, analysis of miR-1236 targets did not yield signature genes necessary for lymphatic signaling in response to VEGF-C such as neuropilin-2. Furthermore, we confirmed that neuropilin-2 levels were not altered by miR-1236 in HLEC and in retina ( Figure 6 ). Because 3Ј UTR analysis revealed that this site is evolutionarily conserved in vertebrates, we decided to test the effect of miR-1236 in vivo. Administration of miR-1236 in vivo caused a significant reduction in tip cells and dysregulated angiogenesis of blood vessels. Moreover, lymphatic density was decreased during postnatal vascular development in tissues examined. These results are consistent with the importance of VEGFR-3 for lymphangiogenesis and angiogenesis. 29 MiR-1236 is an evolutionary recent miRNAas it is only found in Pongo pygmaeus, Pan troglodytes, and Homo sapiens. Because mirtrons are thought to be newly evolved regulators in various animal species with a preexisting canonical miRNA pathway, it is thought that the contribution of mirtrons to the miRNA-mediated regulatory network is smaller than that of canonical miRNAs, owing to their generally modest expression levels. 41 Our data are consistent with this finding. By Northern blot, absolute expression of miR-1236 is low in HLEC. Furthermore, this may explain why knockdown of miR-1236 had a modest effect on VEGFR-3 protein and function in HLEC ( Figure VII in the online-only Data Supplement). It is possible that there may be more mirtrons and conventional miRNAs that target VEGFR-3 mRNA to add to the regulation provided by more highly expressed miRNAs in the traditional pathway. Indeed, knockdown of Dicer in HLECs led to an increase of VEGFR-3 in steady state conditions (not shown), supporting this hypothesis. Nevertheless, our study indicates that miR- 1236 is a miR that targets VEGFR-3, and should provide a foundation for us to define more miRNAs regulating VEGFR-3 signaling and lymphangiogenesis in the context of inflammation. Moreover, the seemingly dual role of IL-1␤ and other inflammatory cytokines in the promotion and resolution of lymphangiogenesis is intriguing. Although IL-1␤ and other inflammatory cytokines mediate inflammation, the kinetics and interplay between these cytokines and lymphangiogenic factors needs further investigation.
